Skip to content
Home/Companies/Pharma/OFI

OFI

Pharma·Italy·Exited 2020·Held 1yr
Entry
2019
Hold
1yr
Exit
2020

Who owns OFI?

OFI was owned by Alto Partners SGR through Alto Capital IV (2017 vintage) from 2019 to 2020, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-19

Alto Partners SGR
Investor
Alto Partners SGR
Alto Capital IV · 2017 · Small-Mid Buyout

Key facts

HQItaly
SectorPharma
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2020

More from Alto Capital IV

Other portfolio companies in the same fund.

CEI (reinvestment)
Active
MobilityItaly· 2022
DMX Pharma
Exited 2025
PharmaItaly· 2022
to
Diatech
Exited 2023
BiotechItaly· 2021
to
CEI
CEI
Exited 2022
MobilityItaly· 2020
to
Bia
Exited 2022
ConsumerItaly· 2019
to
Olimpia Splendid
Olimpia Splendid
Exited 2025
ConstructionItaly· 2019
to

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track OFI

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy OFI?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on OFI.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue